Genotypic Technology Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 17-07-2024
- Paid Up Capital ₹ 2.58 M
as on 17-07-2024
- Company Age 26 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.90 Cr
as on 17-07-2024
- Satisfied Charges ₹ 3.66 M
as on 17-07-2024
- Revenue 60.48%
(FY 2023)
- Profit 62.34%
(FY 2023)
- Ebitda 47.22%
(FY 2023)
- Net Worth 44.48%
(FY 2023)
- Total Assets 29.85%
(FY 2023)
About Genotypic Technology
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.58 M.
The company currently has active open charges totaling ₹6.90 Cr. The company has closed loans amounting to ₹3.66 M, as per Ministry of Corporate Affairs (MCA) records.
Sudha Rao and Raja Mugasimangalam serve as directors at the Company.
- CIN/LLPIN
U72200KA1998PTC049038
- Company No.
049038
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Oct 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Genotypic Technology Private Limited offer?
Genotypic Technology Private Limited offers a wide range of products and services, including Data Entry & Data Processing Service, Data Management, Medical Laboratory Instruments, Corona Test Kit, Diagnostic Imaging & Pathology Labs, Medical Test Services, Inspection & Quality Check Services, Quality Inspection Service.
Who are the key members and board of directors at Genotypic Technology?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raja Mugasimangalam  | Managing Director | 09-Oct-1998 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sudha Rao | Whole-Time Director | 29-Sep-1999 | Current |
Financial Performance and Corporate Structure Insights of Genotypic Technology.
Genotypic Technology Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 60.48% increase. The company also saw a substantial improvement in profitability, with a 62.34% increase in profit. The company's net worth Soared by an impressive increase of 44.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genotypic Technology?
In 2023, Genotypic Technology had a promoter holding of 70.52% and a public holding of 29.48%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Qtlomics Technologies Private LimitedActive 11 years 3 monthsRaja Mugasimangalam is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 25 Mar 2022 | ₹1.41 M | Open |
Siemens Financial Services Private Limited Creation Date: 30 May 2014 | ₹1.40 Cr | Open |
Canara Bank Creation Date: 14 Dec 2012 | ₹1.13 M | Open |
How Many Employees Work at Genotypic Technology?
Genotypic Technology has a workforce of 82 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genotypic Technology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genotypic Technology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
